MIPS reporting requirements could be eliminated

HHS Secretary Alex Azar said he wants to reduce or possibly eliminate reporting requirements for the Merit-based Incentive Payment System (MIPS), instead using claims data and patient surveys so clinicians won’t have to submit any data themselves.

“What we’re doing is taking a whole host of physicians who not only will have reduced reporting burdens but maybe none under the MIPS part of that program,” Azar said to the Senate Finance Committee on Feb. 16.

Paul Ginsburg, PhD, a health policy professor at the University of Southern California and member of the Medicare Payment Advisory Commission (MedPAC), told Morning Consult the change would especially help smaller practices which find the current requirements too expensive. But he also said there would be drawbacks.

“Even though claims data can accurately reflect some aspects of quality, attributing that beneficiary’s quality of care to any physician practice is problematic because so many different physicians and other providers may be involved in that person’s care,” Ginsburg said.

Ginsburg believes the current reporting requirements are ineffective because clinicians can choose the quality measures on which they’re judged. That’s one of the reasons MedPAC has proposed Congress eliminate MIPS and replace it with the Voluntary Value Program (VVP), which pushes physicians toward alternative payment models.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.